Bezlotoxumab is an IV antitoxin infusion treatment option for Clostridium difficile (C. diff) that’s been shown to reduce recurrence in IBD patients…so why isn’t it being used as much as it should be? Here to share the latest data and insights on bezlotoxumab as a treatment option for IBD patients with C. diff is Dr. Jessica Allegretti, Associate Director of the Crohn's and Colitis Center and Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.